Litcius/Paper detail

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Erica J. Brenner, Ryan C. Ungaro, Richard B. Gearry, Gilaad G. Kaplan, Michele Kissous-Hunt, James D. Lewis, Siew C. Ng, Jean‐François Rahier, Walter Reinisch, Frank M. Ruemmele, Flávio Steinwurz, Fox E. Underwood, Xian Zhang, Jean‐Frédéric Colombel, Michael D. Kappelman

2020Gastroenterology692 citationsDOIOpen Access PDF

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Inflammatory Bowel DiseasesAdverse effectTumor necrosis factor alpha2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Inflammatory bowel diseaseInternal medicineIntensive care medicineGastroenterologyVirologyOutbreakDiseaseInfectious disease (medical specialty)Inflammatory Bowel DiseaseCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry | Litcius